

Drug Monograph

Drug Name: **Alkindi® Sprinkle (hydrocortisone) oral granules/capsules**
 Drug Class: **Corticosteroids, Systemic**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Alkindi is available as oral granules within a capsule containing 0.5 mg, 1 mg, 2 mg and 5 mg hydrocortisone.

Manufacturer: Distributed by: Eton Pharmaceuticals, Inc, Deer Park IL, 60010.

Indications: Alkindi is indicated as replacement therapy in pediatric patients with adrenocortical insufficiency.

Costs: For 50-count bottles of the following: \$349.32 for 0.5 mg, \$698.64 for 1 mg, \$1,397.28 for 2 mg, and \$3,493.20 for 5 mg capsules. Wholesale Acquisition Cost

Summary of Findings: The MO HealthNet Division recommends prior authorization status for this product.

Status Recommendation: Clinical Edit PA Required
 Open Access PDL

Type of PA Criteria: Appropriate Indications Non-Preferred
 No PA Required Preferred

Prepared by: Jaci Schowengerdt, PharmD
 Date: January 7, 2021